Overview
- NIH-funded University of Virginia scientists, in Nature, used gene-edited mice and the oral drugs orforglipron and danuglipron to show that activating the central amygdala cuts dopamine release during pleasure feeding.
- The study maps how small-molecule pills reach deep brain regions tied to reward, unlike larger injected peptides, and notes these pills are cheaper to produce and easier to distribute.
- Researchers stress the findings are preclinical and say human studies are needed to test if the same reward-circuit changes occur in people.
- The pathway may clarify why some GLP-1 drugs trigger more nausea while others mainly reduce the drive to seek high-calorie foods.
- Separately, a Japanese observational study reported better long-term results in patients whose overeating is driven by food sights and smells than in those prone to emotional eating, which the authors say requires confirmation in larger trials.